AbbVie, Inc's Earnings Made Easy
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Apr 27, 12:00PM CDT
AbbVie, Inc reported earnings last week, with revenue up 5% year-over-year to $4.6 billion. Adjusted eps grew to $0.71, up 4% from last year and above management's previous guidance range. Humira, the current best-selling drug in the world,...
Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 25, 6:58PM CDT
Cramer is still watching earnings and the continuing crisis in Ukraine.
Hepatitis C Space Heats Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
What looked like a two-horse hepatitis C race between Gilead Sciences and AbbVie has gotten more interesting, with Merck and Bristol-Myers Squibb presenting data on their hepatitis C drugs at a scientific meeting earlier this month. ...
Biotechs' Rocky Road
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 4:28PM CDT
Biotechs have taken a bit of a beating of late, with the Nasdaq Biotechnology Index off 18% from its high in February and flat for the year. There doesn't seem to be any one thing to blame. Instead it's a combination of little things like worry...
Here's What One of America's Richest Investors Has Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Fri Apr 25, 4:14PM CDT
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at Fisher Asset Management, founded in 1979 by Ken Fisher. It...
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 3:45PM CDT
AbbVie (ABBV) surpassed expectations in the first quarter on the back of strong Humira sales.
Federal Circuit Rules for Axinn Client Natco Pharma Ltd. in Tamiflu Patent Appeal
Business Wire - Fri Apr 25, 12:50PM CDT
A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.'s patent on the popular flu drug Tamiflu. The decision could pave the way to Natco's planned issuance of a generic version of the drug in the United States. Natco was represented by Axinn attorneys Jeremy Lowe and Thomas Hedemann.
Most active Nasdaq-traded stocks
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Midday Glance: Biotechnology companies
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'
at Investor's Business Daily - Fri Apr 25, 11:30AM CDT
Big pharma AbbVie (ABBV) beat Q1 estimates Friday and got the Street talking when the company's executives implied that they won't discount their new hepatitis C regimen. Their stock was up 1% in morning trading on the stock market today. AbbVie's...
Early Glance: Biotechnology companies
AP - Fri Apr 25, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.
What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...
Final Glance: Biotechnology companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Alexion Posts Strong Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:00PM CDT
Alexion (ALXN) handsomely beat the Zacks Consensus Estimate in the first quarter.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data